China’s National Key R&D Programmes

Eyedeal Medical successfully held a press conference about the cross-linked polyolefin intraocular lens clinical trial

On November 12, the Press Conference on the Clinical Trial of the World’s Latest Generation of Cross-Linked Polyolefin Intraocular Lenses was successfully held in Xi’an by Xi’an Eyedeal Medical Technology Co., Ltd. This project is a National Key R&D Program. After seven years, the world’s latest generation of cross-linked polyolefin intraocular lens independently developed by our company has obtained a global patent.

Member of the Science and Technology Working Committee of the Provincial Party Committee, Deputy Director of the Provincial Department of Science and Technology Lan Zhuangli; Deputy Director of Xi’an High-tech Zone Management Committee Shi Kangdu; Deputy Inspector of Shaanxi Provincial Department of Science and Technology Xu Shuwei; Director Fan Menghui, Director Xu Haihan, Director Xu Zhenxi; Director Fan Jihong of Shaanxi Provincial Department of Industry and Information Technology; Director Zhao Yuxiao of Xi’an Bureau of Industry and Information Technology; Deputy Director of Biological Medicine Office of Xi’an High-tech Zone Su Juan; Xi’an Fourth Hospital, Shaanxi Prof. Yan Hong, President of the Provincial Eye Hospital and Chairman of the Shaanxi Provincial Medical Association Ophthalmology Branch; Guo Guangxu, Chairman and CEO of Xi’an Eyedeal, Dr. Yang Zhou, Chief Technology Officer, Ms. Yang Min, Senior Vice President, and Ms. Peng Qun, Chief Medical Officer attended this conference.

Currently, foldable intraocular lenses are monopolized by international giants, and the domestic share is extremely limited. The new generation of cross-linked polyolefin material independently developed by our company for seven years has obtained a global patent. Our intraocular lens has the advantages of no calcification, no flare, less inflammatory reaction, and low incidence of later failure. At the same time, the intraocular lens has a large optical surface, good imaging effect, small chromatic aberration and high image quality. The material has a large stretching rate, requires small surgical incisions, and features a quick recovery time, meeting people’s requirements for higher-quality vision, not only seeing, but also seeing clearly, comfortably over the long term.

Right now, our company is carrying out multi-center clinical trials across the country, which will be conducted by Prof. Zhao Yun’e from Wenzhou Medical University Affiliated Ophthalmology Hospital, Prof. Bao Yongzhen from Peking University People’s Hospital, Prof. Yan Hong from Xi’an Fourth Hospital and Shaanxi Provincial Eye Hospital, Shandong University of Traditional Chinese Medicine Prof. Bi Hongsheng from Affiliated Eye Hospital, Prof. Zhang Mingzhi from Shantou University, Chinese University of Hong Kong and Shantou International Ophthalmology Center, Prof. Xia Xiaobo from Xiangya Hospital of Central South University, Prof. Song Hui from Tianjin Eye Hospital, Prof. Wu Zhengzheng from Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, jointly carried out by Professor Fan Wei from West China Hospital of Sichuan University. The entry of the project into a clinical trial means that the preliminary research and development of the project has been completed, and the product launch and large-scale mass production are just around the corner.

Guo Guangxu, Chairman and CEO of Eyedeal, told reporters at the press conference: “As a national enterprise rooted in Shaanxi, gathering global innovative talents and scientific and technological achievements, and concentrating on conquering key bottlenecked medical technology, Xi’an Eyedeal Medical Technology Co., Ltd. actively explores the wide application of new patented materials in the field of other implantable medical devices. As an industry-leading ophthalmic medical device company, it will continue to provide ideal and perfect products and services to customers around the world.